Advertisement
Canada markets open in 8 hours 51 minutes
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7323
    +0.0000 (+0.00%)
     
  • CRUDE OIL

    83.86
    +0.29 (+0.35%)
     
  • Bitcoin CAD

    87,750.45
    -30.14 (-0.03%)
     
  • CMC Crypto 200

    1,386.31
    +3.74 (+0.27%)
     
  • GOLD FUTURES

    2,348.40
    +5.90 (+0.25%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,771.00
    +203.50 (+1.16%)
     
  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • NIKKEI 225

    37,946.66
    +318.18 (+0.85%)
     
  • CAD/EUR

    0.6827
    +0.0006 (+0.09%)
     

Tilray: Analysts’ Target Price and Ratings in December

Tilray: Analysts’ Target Price and Ratings in December

Tilray (TLRY) has been among the most volatile stocks compared to other cannabis players (MJ) including Canopy Growth (WEED), Aurora Cannabis (ACBFF), and Aphria (APHQF). The company has returned nearly 241% since its debut in July. Tilray has garnered a lot of attention since its IPO. Earlier this week, the company announced a partnership with Novartis to make co-branded products for international markets.